Graham Samuel-Gibbon

Graham is an international tax specialist. He advises domestic and multinational clients on a wide range of transactional and advisory tax matters. Graham regularly works with FTSE 100 and Future Global 100 companies.

He guides clients through stock and asset/business acquisitions and disposals, crossborder tax structuring, UK inbound and outbound investment, joint ventures and reorganisations.

He also advises on tax issues relating to the development, ownership and exploitation of intellectual property rights, with a particular focus on the life science and technology sectors.

显示完整简历隐藏完整简历

职业发展

Since 2017	Partner, Taylor Wessing
2014 - 2017	Director, EY
2007 - 2014	Senior Associate, Latham & Watkins

2005 - 2007

Associate, Hogan Lovells

更多更少

教育

2001	Master's Degree, Jurisprudence II, University of Oxford, UK
2000	French Law, Université Panthéon Assas, Paris II, France

语言

English

French

专长

执业领域和服务团队税收公司税/并购税安排/交易税收媒体与知识产权税收

行业技术、媒体与通信 (TMC)消费与零售酒店与休闲酒店与休闲制造业与工业金融科技

Experience

Babylon Health continues to invest in digital healthcare with largest European and US fundraising	Babylon Health, a UK-based digital health subscription provider, on its USD550m fundraising to support expansion into the US and Asia. This is the largest ever fundraising in the European or US digital health sector and values Babylon at over USD2bn. Investors included PIF, ERGO Fund, Kinnevik and Vostok New Ventures.
Secret Escapes on the acquisition of TravelBird and Pigsback.com	Secret Escapes on the acquisition of Dutch based TravelBird, the online luxury and experience company, and Pigsback.com, the market leading marketplace in Ireland for online hospitality offers.
World's longest standing cryptocurrency exchange, Bitstamp, sells 80% stake to NXMH	We advised on the 80% sale of Bitstamp to Brussels-based investment firm, NXMH. Founded in the UK in 2011, Bitstamp is the world's longest standing cryptocurrency exchange and the EU's largest by volume, with more than three million registered customers.

A FTSE 100 multinational pharmaceutical group	A FTSE 100 multinational pharmaceutical group on onshoring its intellectual property portfolio.
A FTSE 100 global biotechnology group	A FTSE 100 global biotechnology group on its post-merger integration of local operating companies across over 30 jurisdictions.
A FTSE 100 pharmaceutical group	A FTSE 100 pharmaceutical group on a +USD10bn disposal of a therapeutic business line and on the establishment of a joint venture of its consumer products business.